<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152960">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812590</url>
  </required_header>
  <id_info>
    <org_study_id>Ex-Panc</org_study_id>
    <nct_id>NCT01812590</nct_id>
  </id_info>
  <brief_title>Acute Exercise and Pancreatic Endocrine Function</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with type 2 diabetes will be stratified into two-quantiles based on ambient
      hyperglycemia (fasting glucose and HbA1c) and then the effects of a single aerobic exercise
      bout (1-hour at 50%VO2max) on pancreatic endocrine function will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pancreatic endocrine function</measure>
    <time_frame>24-hours following a period of rest/exercise</time_frame>
    <safety_issue>No</safety_issue>
    <description>Insulin and glucagon secretory responses to intravenous glucose (hyperglycemic clamp 5.4 mmol/l above basal), glucagon-like peptide-1 (0.5 pmol/kg/min), and arginine (5 g injection) will be determined.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Resting Trial</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pancreatic endocrine function will be determined the morning following a day where no exercise is performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise Trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <arm_group_label>Exercise Trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous diagnosis with type 2 diabetes, or newly detected in our screening
             procedures

          -  Age 30-70 years

          -  BMI 20-40 kg/m2

        Exclusion Criteria:

          -  Treatment with insulin

          -  Contraindication to exercise as determined by ECG

          -  Pregnancy

          -  Active weight loss in the previous 6 months

          -  Actively engaged in exercise training programs

          -  Evidence of chronic pulmonary, cardiovascular, hepatic, renal, or hematological
             disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Solomon</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
